Haplotyping in patients with genetically proven Myotonic Dystrophy type 2

Haplotyping in patients with genetically proven Myotonic Dystrophy type 2 - DM2 haplotype

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43063

Enrollment

Registered

2017-01-12

Start date

2017-06-02

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic Dystrophy type 2 Proximal Myotonic Myopathy (PROMM)

Interventions

autoimmune dissease

Haplotype

myotonic dystrophy type 2

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: genetically proven DM2, minimum age: 18 years old

Exclusion criteria

Exclusion criteria: n.a.

Design outcomes

Primary

Measure	Time frame
Will the genetic material in the 3q21.3 region be the same in all patients with DM2	—

Secondary

Measure	Time frame
Do DM2 patients with an autoimmune disease have a different haplotype than that of DM2 patients without an autoimmune disease.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)